Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CHEK-ATP157 | Human | HEK293/Human NGFR Stable Cell Line | |||
NGR-H5254 | Human | Human NGFR / TNFRSF16 Protein, Fc Tag (MALS verified) |
|
|
Expression analysis of human NGFR on HEK293/Human NGFR Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human NGFR Stable Cell Line or negative control cell using PE-labeled anti-human NGFR antibody after fixation with 4% paraformaldehyde.
Loaded Human NGFR Protein, Fc Tag (Cat. No. NGR-H5254) on Protein A Biosensor, can bind Human NT-4, Tag Free (Cat. No. NT4-H5114) with an affinity constant of 1.64 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
The purity of Human NGFR Protein, Fc Tag (Cat. No. NGR-H5254) is more than 95% and the molecular weight of this protein is around 115-135 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cenegermin | rhNGF (Dompe Farmaceutici) | Approved | Dompe Farmaceutici Spa | 欧适维, Sentinel, Oxervate | EU | Keratitis | Dompé Pharmaceutici Spa | 2017-07-06 | Keratitis; Corneal Ulcer; Corneal Diseases; Dry Eye Syndromes; Retinitis Pigmentosa; Eye Diseases; Mental Disorders | Details |
Mouse nerve growth factor (Wuhan Hiteck Bio-pharmaceutical) | Approved | Wuhan Hiteck Biological Pharma Co Ltd | 金路捷 | Mainland China | Trauma, Nervous System | Wuhan Hiteck Biological Pharma Co Ltd | 2002-01-01 | Optic Nerve Injuries; Trauma, Nervous System | Details | |
Mouse nerve growth factor (Livzon Group) | Approved | Livzon Pharmaceutical Group Inc | 丽康乐 | Mainland China | Optic Nerve Injuries | Livzon(Group) Pharmaceutical Factory | 2010-05-07 | Optic Nerve Injuries | Details | |
Mouse nerve growth factor (Staidson Biopharma) | Approved | Staidson(Beijing) Biopharmaceuticals Co Ltd | 苏肽生 | Mainland China | Optic Nerve Injuries | Staidson(Beijing) Biopharmaceuticals Co Ltd | 2006-04-11 | Diabetic Foot; Optic Nerve Injuries; Peripheral Nerve Injuries | Details | |
Cenegermin | rhNGF (Dompe Farmaceutici) | Approved | Dompe Farmaceutici Spa | 欧适维, Sentinel, Oxervate | EU | Keratitis | Dompé Pharmaceutici Spa | 2017-07-06 | Keratitis; Corneal Ulcer; Corneal Diseases; Dry Eye Syndromes; Retinitis Pigmentosa; Eye Diseases; Mental Disorders | Details |
Mouse nerve growth factor (Wuhan Hiteck Bio-pharmaceutical) | Approved | Wuhan Hiteck Biological Pharma Co Ltd | 金路捷 | Mainland China | Trauma, Nervous System | Wuhan Hiteck Biological Pharma Co Ltd | 2002-01-01 | Optic Nerve Injuries; Trauma, Nervous System | Details | |
Mouse nerve growth factor (Livzon Group) | Approved | Livzon Pharmaceutical Group Inc | 丽康乐 | Mainland China | Optic Nerve Injuries | Livzon(Group) Pharmaceutical Factory | 2010-05-07 | Optic Nerve Injuries | Details | |
Mouse nerve growth factor (Staidson Biopharma) | Approved | Staidson(Beijing) Biopharmaceuticals Co Ltd | 苏肽生 | Mainland China | Optic Nerve Injuries | Staidson(Beijing) Biopharmaceuticals Co Ltd | 2006-04-11 | Diabetic Foot; Optic Nerve Injuries; Peripheral Nerve Injuries | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Mouse nerve growth factor (Sinobioway Biomedicine) | Phase 3 Clinical | Sinobioway Biomedicine Co Ltd | Diabetic Foot; Optic Nerve Injuries | Details | |
Choroid plexus cell replacement therapy (Living Cell Technologies) | Phase 3 Clinical | Living Cell Technologies | Surgical Wound Infection | Details | |
Recombinant human nerve growth factor (Sichuan ZehaTimes Pharmaceutical) | Phase 2 Clinical | Sichuan ZehaTimes Pharmaceutical Co Ltd | Optic Nerve Injuries | Details | |
Recombinant human nerve growth factor(Sinobioway Biomedicine) | SMR001; SMR-001 | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Xerophthalmia | Details |
Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Keratitis; Optic Nerve Injuries; Glaucoma, Open-Angle | Details |
CHF-6467 | CHF-6467 | Phase 2 Clinical | Chiesi Farmaceutici SPA | Diabetic Foot | Details |
Udonitrectag | REC-0559; MT-8; REC 0/0559 | Phase 2 Clinical | Mimetech SRL | Keratitis | Details |
Recombinant human nerve growth factor(Chongqing Kerun Biologic) | Phase 1 Clinical | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | Keratitis | Details | |
CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details | |
Mouse nerve growth factor (Sinobioway Biomedicine) | Phase 3 Clinical | Sinobioway Biomedicine Co Ltd | Diabetic Foot; Optic Nerve Injuries | Details | |
Choroid plexus cell replacement therapy (Living Cell Technologies) | Phase 3 Clinical | Living Cell Technologies | Surgical Wound Infection | Details | |
Recombinant human nerve growth factor (Sichuan ZehaTimes Pharmaceutical) | Phase 2 Clinical | Sichuan ZehaTimes Pharmaceutical Co Ltd | Optic Nerve Injuries | Details | |
Recombinant human nerve growth factor(Sinobioway Biomedicine) | SMR001; SMR-001 | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Xerophthalmia | Details |
Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Keratitis; Optic Nerve Injuries; Glaucoma, Open-Angle | Details |
CHF-6467 | CHF-6467 | Phase 2 Clinical | Chiesi Farmaceutici SPA | Diabetic Foot | Details |
Udonitrectag | REC-0559; MT-8; REC 0/0559 | Phase 2 Clinical | Mimetech SRL | Keratitis | Details |
Recombinant human nerve growth factor(Chongqing Kerun Biologic) | Phase 1 Clinical | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | Keratitis | Details | |
CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details |
This web search service is supported by Google Inc.